Your browser doesn't support javascript.
loading
Neutropenia inducida por citostáticos en oncología / Neutropenia induced by cytostatics in oncology
León Barrios, Yeris Leydis; Céspedes Quevedo, María Cristina; Vinent Céspedes, Ana Margarita.
  • León Barrios, Yeris Leydis; Hospital Oncológico Docente Provincial Conrado Benítez García. Santiago de Cuba. CU
  • Céspedes Quevedo, María Cristina; Hospital Oncológico Docente Provincial Conrado Benítez García. Santiago de Cuba. CU
  • Vinent Céspedes, Ana Margarita; Hospital Oncológico Docente Provincial Conrado Benítez García. Santiago de Cuba. CU
Medisan ; 21(11)nov. 2017. ta, graf
Article in Spanish | LILACS | ID: biblio-894575
RESUMEN
Se realizó un estudio descriptivo y transversal de 330 pacientes con cáncer, atendidos en el Hospital Oncológico Conrado Benítez de Santiago de Cuba, desde junio hasta diciembre del 2014, para determinar la presencia de neutropenias inducidas por quimioterapia. Presentaron esa afección 145 pacientes (44,0 por ciento). Predominaron el grupo etario de 41-60 años (51,0 por ciento), el sexo femenino (87,5 por ciento), el cáncer de mama (64,8 por ciento), el estadio clínico II (50,3 por ciento), los afectados con 2 episodios de neutropenia (62,1 por ciento), así como los grados leve (51,7 por ciento) y moderado (37,9 por ciento). Respondieron al tratamiento con ior® LeukoCIM 118 pacientes (81,4 por ciento). No se estableció asociación entre las diferentes combinaciones de citostáticos, el número de episodios y los grados de esa enfermedad. La disponibilidad del ior® LeukoCIM para tratar dicha afección facilitará su uso profiláctico y mejorará la calidad de vida de estos pacientes
ABSTRACT
A descriptive and cross-sectional study of 330 patients with cancer, assisted in Conrado Benítez Oncological Hospital in Santiago de Cuba, was carried out from June to December, 2014, to determine the presence of neutropenias induced by chemotherapy. This disorder was present in 145 patients (44.0 percent). There was a prevalence of the 41-60 age group (51.0 percent), female sex (87.5 percent), breast cancer (64.8 percent), clinical stage II (50.3 percent), those affected patients with 2 neutropenia episodes (62.1 percent), as well as light (51.7 percent) and moderate grades (37.9 percent). One hundred eighteen patients responded to the treatment with ior® LeukoCIM (81.4 percent). There was no association between the different combinations of cytostatics, number of episodes and grades of that disease. The availability of the ior® LeukoCIM to treat this disorder will facilitate its prophylactic use and will improve these patients life quality
Subject(s)

Full text: Available Index: LILACS (Americas) Main subject: Agranulocytosis / Cytostatic Agents / Chemotherapy-Induced Febrile Neutropenia / Neoplasms Type of study: Observational study / Prevalence study / Risk factors Limits: Female / Humans / Male Language: Spanish Journal: Medisan Journal subject: Medicine Year: 2017 Type: Article Affiliation country: Cuba Institution/Affiliation country: Hospital Oncológico Docente Provincial Conrado Benítez García/CU

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Index: LILACS (Americas) Main subject: Agranulocytosis / Cytostatic Agents / Chemotherapy-Induced Febrile Neutropenia / Neoplasms Type of study: Observational study / Prevalence study / Risk factors Limits: Female / Humans / Male Language: Spanish Journal: Medisan Journal subject: Medicine Year: 2017 Type: Article Affiliation country: Cuba Institution/Affiliation country: Hospital Oncológico Docente Provincial Conrado Benítez García/CU